Investors question Nestlé CHC move
This article was originally published in OTC Bulletin & The Rose Sheet
Swiss food and drinks giant Nestlé should “better explain to shareholders the rationale behind expanding further into consumer healthcare”,says major shareholder Third Point.
You may also be interested in...
Marketer long known for iconic Hershey's Kisses and other candy products looks to grow its nutritional market revenues with One Brands' products, complementing its Oatmega business and following its investment earlier in August in UK/Ireland maker of protein bars.
US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.